company background image
NXS logo

Next Science CHIA:NXS Stock Report

Last Price

AU$0.09

Market Cap

AU$25.1m

7D

-9.1%

1Y

-71.0%

Updated

18 May, 2025

Data

Company Financials +

Next Science Limited

CHIA:NXS Stock Report

Market Cap: AU$25.1m

NXS Stock Overview

Engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. More details

NXS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Revenue is forecast to grow 17.8% per year

Trading at good value compared to peers and industry

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the Australian market

Does not have a meaningful market cap (A$25M)


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Next Science Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Next Science
Historical stock prices
Current Share PriceAU$0.09
52 Week HighAU$0.32
52 Week LowAU$0.081
Beta1.31
1 Month Change-10.00%
3 Month Change-25.00%
1 Year Change-70.97%
3 Year Change-89.60%
5 Year Change-94.36%
Change since IPO-93.16%

Recent News & Updates

Recent updates

Shareholder Returns

NXSAU Medical EquipmentAU Market
7D-9.1%0.4%1.3%
1Y-71.0%-12.1%5.0%

Return vs Industry: NXS underperformed the Australian Medical Equipment industry which returned -12.1% over the past year.

Return vs Market: NXS underperformed the Australian Market which returned 5% over the past year.

Price Volatility

Is NXS's price volatile compared to industry and market?
NXS volatility
NXS Average Weekly Movement12.9%
Medical Equipment Industry Average Movement12.2%
Market Average Movement9.5%
10% most volatile stocks in AU Market16.8%
10% least volatile stocks in AU Market4.1%

Stable Share Price: NXS's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: NXS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2012n/aI.V. Hallwww.nextscience.com

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Next Science Limited Fundamentals Summary

How do Next Science's earnings and revenue compare to its market cap?
NXS fundamental statistics
Market capAU$25.13m
Earnings (TTM)-AU$16.53m
Revenue (TTM)AU$35.62m

0.7x

P/S Ratio

-1.5x

P/E Ratio

Is NXS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NXS income statement (TTM)
RevenueUS$22.82m
Cost of RevenueUS$4.37m
Gross ProfitUS$18.44m
Other ExpensesUS$29.03m
Earnings-US$10.59m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.036
Gross Margin80.83%
Net Profit Margin-46.40%
Debt/Equity Ratio52.5%

How did NXS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 10:09
End of Day Share Price 2025/05/16 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Next Science Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shane StoreyWilsons Advisory and Stockbroking Ltd.
Shane StoreyWilsons Advisory and Stockbroking Ltd.